Industry
Biotechnology
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Lisa Levin
September 21, 2023 | 11:51 am
Portfolio Pulse from Lisa Levin
September 20, 2023 | 6:10 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2023 | 2:44 pm
Portfolio Pulse from Benzinga Newsdesk
September 19, 2023 | 11:38 am
Portfolio Pulse from Benzinga Insights
September 15, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Insights
August 21, 2023 | 5:31 pm
Portfolio Pulse from richadhand@benzinga.com
August 11, 2023 | 11:00 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.